Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $55,346 | 18 | 62.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $22,975 | 5 | 25.7% |
| Travel and Lodging | $6,282 | 16 | 7.0% |
| Honoraria | $2,775 | 2 | 3.1% |
| Food and Beverage | $1,725 | 23 | 1.9% |
| Education | $178.06 | 3 | 0.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $23,573 | 13 | $0 (2022) |
| Alexion Pharmaceuticals, Inc. | $20,128 | 12 | $0 (2024) |
| SOBI, INC | $13,202 | 8 | $0 (2023) |
| PFIZER INC. | $9,523 | 10 | $0 (2024) |
| GENZYME CORPORATION | $9,050 | 6 | $0 (2023) |
| Janssen Scientific Affairs, LLC | $4,360 | 4 | $0 (2024) |
| Agios Pharmaceuticals, Inc. | $2,775 | 2 | $0 (2023) |
| Alnylam Pharmaceuticals Inc. | $2,760 | 1 | $0 (2024) |
| Janssen Global Services, LLC | $2,180 | 1 | $0 (2023) |
| Janssen Pharmaceuticals, Inc | $1,250 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $23,620 | 17 | Alexion Pharmaceuticals, Inc. ($16,128) |
| 2023 | $21,161 | 14 | PFIZER INC. ($7,062) |
| 2022 | $16,889 | 13 | Sobi, Inc ($10,427) |
| 2021 | $1,013 | 4 | GENZYME CORPORATION ($851.00) |
| 2020 | $13,326 | 5 | Novartis Pharmaceuticals Corporation ($10,586) |
| 2019 | $11,134 | 10 | Novartis Pharmaceuticals Corporation ($10,962) |
| 2017 | $2,137 | 4 | PFIZER INC. ($2,137) |
All Payment Transactions
67 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/29/2024 | Janssen Scientific Affairs, LLC | — | Consulting Fee | Cash or cash equivalent | $953.75 | General |
| 11/13/2024 | CSL Behring | HEMGENIX (Biological) | Food and Beverage | In-kind items and services | $17.92 | General |
| Category: Hematology | ||||||
| 10/21/2024 | Alexion Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $13,260.00 | General |
| 10/21/2024 | Alexion Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $728.97 | General |
| 10/21/2024 | Alexion Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $74.98 | General |
| 10/21/2024 | Alexion Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $69.90 | General |
| 10/20/2024 | Alexion Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $1,458.10 | General |
| 10/20/2024 | Alexion Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $303.15 | General |
| 09/30/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Rare Disease | ||||||
| 08/22/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $58.60 | General |
| Category: Rare Disease | ||||||
| 06/13/2024 | Alnylam Pharmaceuticals Inc. | GIVLAARI (Drug) | Consulting Fee | Cash or cash equivalent | $2,760.00 | General |
| Category: Genetic Disease | ||||||
| 05/15/2024 | Janssen Scientific Affairs, LLC | — | Consulting Fee | Cash or cash equivalent | $1,090.00 | General |
| 05/15/2024 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Education | Cash or cash equivalent | $6.11 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 04/02/2024 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,250.00 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 02/26/2024 | Janssen Scientific Affairs, LLC | — | Consulting Fee | Cash or cash equivalent | $1,090.00 | General |
| 01/17/2024 | PFIZER INC. | OXBRYTA (Drug) | Travel and Lodging | In-kind items and services | $324.04 | General |
| Category: HEMATOLOGY | ||||||
| 01/11/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $49.42 | General |
| Category: Rare Disease | ||||||
| 12/11/2023 | Janssen Scientific Affairs, LLC | — | Consulting Fee | Cash or cash equivalent | $1,226.25 | General |
| 11/10/2023 | PFIZER INC. | OXBRYTA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,975.00 | General |
| Category: HEMATOLOGY | ||||||
| 11/02/2023 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Consulting Fee | Cash or cash equivalent | $3,900.00 | General |
| Category: Rare Disease | ||||||
| 10/07/2023 | PFIZER INC. | OXBRYTA (Drug) | Travel and Lodging | In-kind items and services | $506.54 | General |
| Category: HEMATOLOGY | ||||||
| 10/07/2023 | PFIZER INC. | OXBRYTA (Drug) | Food and Beverage | In-kind items and services | $223.31 | General |
| Category: HEMATOLOGY | ||||||
| 10/07/2023 | PFIZER INC. | OXBRYTA (Drug) | Travel and Lodging | In-kind items and services | $216.41 | General |
| Category: HEMATOLOGY | ||||||
| 10/07/2023 | PFIZER INC. | OXBRYTA (Drug) | Travel and Lodging | In-kind items and services | $140.96 | General |
| Category: HEMATOLOGY | ||||||
| 09/26/2023 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Honoraria | Cash or cash equivalent | $832.50 | General |
| Category: Genetically Defined Disease | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 385 | 676 | $139,781 | $55,145 |
| 2022 | 6 | 320 | 622 | $132,519 | $53,911 |
| 2021 | 7 | 382 | 609 | $111,179 | $48,796 |
| 2020 | 7 | 381 | 634 | $106,295 | $43,808 |
All Medicare Procedures & Services
29 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 144 | 314 | $55,700 | $22,980 | 41.3% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 63 | 66 | $26,488 | $9,188 | 34.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 63 | 133 | $19,972 | $8,490 | 42.5% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 42 | 82 | $17,588 | $7,379 | 42.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 38 | 38 | $10,258 | $3,910 | 38.1% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 23 | 23 | $6,210 | $1,622 | 26.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 12 | 20 | $3,565 | $1,574 | 44.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 135 | 327 | $55,342 | $23,837 | 43.1% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 71 | 172 | $36,464 | $14,016 | 38.4% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 68 | 76 | $30,248 | $11,994 | 39.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 19 | 19 | $4,881 | $1,782 | 36.5% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 15 | 15 | $4,050 | $1,633 | 40.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 12 | 13 | $1,534 | $648.71 | 42.3% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 76 | 182 | $38,584 | $15,119 | 39.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 84 | 164 | $25,227 | $13,160 | 52.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 56 | 75 | $11,490 | $5,198 | 45.2% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 45 | 47 | $12,690 | $5,168 | 40.7% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 19 | 20 | $7,960 | $3,229 | 40.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 37 | 46 | $4,548 | $2,411 | 53.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 35 | 40 | $3,960 | $1,742 | 44.0% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 15 | 15 | $3,760 | $1,669 | 44.4% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 15 | 20 | $2,960 | $1,101 | 37.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 136 | 308 | $47,124 | $19,220 | 40.8% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 63 | 65 | $17,550 | $7,439 | 42.4% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 41 | 77 | $16,324 | $6,605 | 40.5% |
About Dr. Michael Jaglal, MD
Dr. Michael Jaglal, MD is a Internal Medicine healthcare provider based in Tampa, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/30/2006. The National Provider Identifier (NPI) number assigned to this provider is 1417024746.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Jaglal, MD has received a total of $89,280 in payments from pharmaceutical and medical device companies, with $23,620 received in 2024. These payments were reported across 67 transactions from 17 companies. The most common payment nature is "Consulting Fee" ($55,346).
As a Medicare-enrolled provider, Jaglal has provided services to 1,468 Medicare beneficiaries, totaling 2,541 services with total Medicare billing of $201,659. Data is available for 4 years (2020–2023), covering 29 distinct procedure/service records.
Practice Information
- Specialty Internal Medicine
- Other Specialties Hospitalist, Hematology & Oncology
- Location Tampa, FL
- Active Since 11/30/2006
- Last Updated 06/02/2025
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1417024746
Products in Payments
- PROMACTA (Drug) $14,770
- DOPTELET (Drug) $10,427
- OXBRYTA (Drug) $7,386
- ADAKVEO (Biological) $6,778
- ULTOMIRIS (Biological) $4,185
- CABLIVI (Biological) $3,707
- Doptelet (Drug) $2,775
- PYRUKYND (Drug) $2,775
- GIVLAARI (Drug) $2,760
- SARCLISA (Biological) $2,403
- ELIQUIS (Drug) $2,137
- XARELTO (Drug) $1,250
- UBRELVY (Drug) $121.15
- GVOKE HYPOPEN (Drug) $82.41
- IMBRUVICA (Drug) $76.95
- XOSPATA (Drug) $40.91
- MONOFERRIC (Drug) $39.24
- HEMGENIX (Biological) $17.92
- Rezlidhia (Drug) $6.11
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Tampa
Javier Pinilla-Ibarz, Md, MD
Internal Medicine — Payments: $1.9M
Alberto Chiappori, Md, MD
Internal Medicine — Payments: $617,120
Ricardo Restrepo-Jaramillo, M.d, M.D
Internal Medicine — Payments: $562,511
Dr. Sady Alpizar, Md, MD
Internal Medicine — Payments: $509,824
Jhanelle Gray, Md, MD
Internal Medicine — Payments: $273,892
Dr. Andrew Kuykendall, M.d, M.D
Internal Medicine — Payments: $273,357